Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized double-blind trial of BIO101 to prevent respiratory deterioration in hospitalized severe COVID-19 pneumonia
2020-001498-63Phase 2Completed
- Sponsor
- Biophytis
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia comparing BIO101 with Placebo (2 arms). Primary endpoints: Primary endpoint (overall study) and Primary endpoint for end-of-part-1 interim analysis. Started Apr 2020; status: completed.
02
Drugs
20-hydroxyecdysone
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001498-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001498-63.